BioHarvest Sciences Inc. Common Stock (BHST) Stock Price & Analysis
BioHarvest Sciences Inc. Common Stock (BHST) closed at USD 1.7 on Thursday, October 15, 2026, down 2.58% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.75; the Oct 15, 2026 session ranged USD 1.53–1.77 on volume of 12,759 shares. Market capitalization is $38.54M, with a 52-week range of USD 1.37–12.2 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BHST.md
Key facts (BHST)
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 10.5 (range 5–15).
- Total return with dividends: 1Y -85.2% vs S&P 500 +18.1%; 5Y -82.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.14, revenue estimate $9.3M.
Analysts (BHST)
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 10.5 (low 5, high 15).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-12 | Maxim Group | Target lowered | Buy | $12 → $5 |
| 2026-08-12 | Roth Capital | Target lowered | Buy | $10 → $8 |
Total return (dividends reinvested) (BHST)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -85.2% | -82.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -85.3% | -29.2% |
| Volatility (annualized) | 66.4% | 65.8% |
| Max drawdown | -87.8% (Oct 2025→Sep 2026) | -89.5% (Jan 2022→Sep 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 1.7 |
|---|---|
| Change | ▼ 2.58% (down) |
| Previous Close | USD 1.75 |
| Open | USD 1.77 |
| Day Range | USD 1.53 – 1.77 |
| 52-Week Range | USD 1.37 – 12.2 |
| Volume | 12,759 shares |
| Market Cap | $38.54M |
| Exchange | NGM |
Technical Analysis (BHST)
Nexqual's technical model rates BHST "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 54.83 (neutral) |
| vs SMA50 | Below (USD 1.8) |
| MACD | -0.03 (negative) |
Analyst Ratings (BHST)
Wall Street analysts rate BHST "Buy" based on 4 analysts, with a mean price target of USD 10.5 (range USD 5–15), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 10.5 |
| High Target | USD 15 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (BHST)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.14 |
| Revenue Estimate | $9.31M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.17 vs est -0.12 ▼ miss |
| 2026-03-31 | USD -0.11 vs est -0.12 ▲ beat |
| 2025-12-31 | USD -0.1 vs est -0.11 ▲ beat |
| 2025-09-30 | USD -0.14 vs est -0.12 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (BHST)
| Total Revenue | $35.48M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +3.80% |
| Gross Margin | +58.95% |
| Operating Margin | -28.37% |
| Profit Margin | -31.21% |
| ROE | -142.50% |
| Debt / Equity | 0.79 |
| Current Ratio | 2.24 |
| Total Cash | $16.22M |
| Total Debt | $15.70M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (BHST)
Nexqual rates BioHarvest Sciences Inc. Common Stock's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Strong — Revenue +37% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $16M cash vs $16M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$9M (TTM) |
| Efficiency | Critical — ROE -143%, ROA -11.0% |
Ownership (BHST)
| Insider Ownership | +14.77% |
|---|---|
| Institutional Ownership | +7.54% |
| Shares Outstanding | 22.67M |
| Float | 19.32M |
| Short % of Float | +0.51% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (BHST)
BioHarvest Sciences Inc. Common Stock is led by Zaki Rakib (age 66), Co-Founder, CEO, Executive Chairman & President, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Co-Founder, CEO, Executive Chairman & President | Zaki Rakib (age 66) |
|---|---|
| Co-Founder & CTO | Yoheved Hagay (age 67) |
| Chief Financial Officer | Bar Dichter |
| Chief Operating Officer | Ilana Belzer (age 65) |
| Vice President of Research & Development | Malkit Azachi |
Major Backers & Investors (BHST)
Notable institutional backers of BioHarvest Sciences Inc. Common Stock include Alyeska Investment Group, L.p., Thompson, Siegel & Walmsley LLC, Evercore Wealth Management, LLC, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Alyeska Investment Group, L.p. | 3.54% |
| Thompson, Siegel & Walmsley LLC | 2.22% |
| Evercore Wealth Management, LLC | 1.32% |
| True North Advisors, LLC | 1.14% |
| Magnus Financial Group LLC | 0.55% |
| Silverberg Bernstein Capital Management LLC | 0.5% |
| Susquehanna International Group, LLP | 0.39% |
| King Luther Capital Management | 0.24% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CPB | The Campbell's Company | USD 19.84 | ▲ 4.7% |
| INGR | Ingredion Incorporated | USD 97.27 | ▲ 0.01% |
| CAG | ConAgra Brands, Inc. | USD 14.18 | ▲ 3.5% |
| PPC | Pilgrim's Pride Corporation | USD 28.89 | ▲ 0.35% |
| SFD | Smithfield Foods, Inc. | USD 18.48 | ▲ 1.43% |
| LW | Lamb Weston Holdings, Inc. | USD 54.21 | ▲ 4.33% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt